#FGFRinhibitor
LightNews LightNews
gmj-georgia.bsky.social
Major milestone: Phase 3 trial shows infigratinib increases growth velocity by 50–60% in children with achondroplasia—the first oral disease-mo…

#Achondroplasia #FGFRinhibitor #Geneticdisorder #Infigratinib #Paediatricmedicine

#Achondroplasia #FGFRinhibitor #Geneticdisorder #Infigratinib #Paedi…
New oral drug shows 50% growth gain in achondroplasia
Major milestone: Phase 3 trial shows infigratinib increases growth velocity by 50–60% in children with achondroplasia—the first oral disease-mo… #Achondroplasia #FGFRinhibitor #Geneticdisorder #Infigratinib #Paediatricmedicine
news.gmj.ge
August 12, 2026 at 5:29 PM
pharmaphorum.bsky.social
#JohnsonandJohnson has revealed early clinical data with a new formulation of its #FGFRinhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage #bladdercancer.

pharmaphorum.com/news/jj-says...
J&J says Inlexzo follow-up 'promising' in bladder cancer
Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
pharmaphorum.com
March 16, 2026 at 10:35 AM